The analysis of network pharmacology shows that inflammation is probably a mechanism for Asp G against PD, and MMP9 may be a potential anti-PD target of Asp G. The findings confirm that Asp G dramatically reduces the overproduction of LPS-stimulated proinflammatory-related mediators and factors. Here, MMP9 is linked to Parkinson disease.